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ATTIVITÀ DI RICERCA 
Durante il Dottorato di Ricerca mi sono occupato dello studio di “cell wall proteins” 
(Cwp) di Clostridium difficile utilizzando due diversi approcci. In particolare ho determinato 
la presenza, la sequenza e la variabilità d'espressione di antigeni identificati come putative 
Cwp tramite un approccio di Reverse Vaccinology. Inoltre, mediante la tecnologia del protein 
microarray, ho analizzato se tali proteine sono esposte sulla superficie batterica durante 
l’infezione e capaci di indurre una risposta immunitaria in hamsters infetti da C. difficile. Tra 
le tecnologie utilizzate nel mio studio rientrano : clonaggio, espressione e purificazione di 
proteine antigeniche di C. difficile, l’utilizzo di protein microarrays per l’analisi di sieri 
umani e di animali, la manipolazione di isolati clinici di C. difficile e studi di epidemiologia 
molecolare tramite l’utilizzo di software specifici. 
Nel periodo del Dottorato di Ricerca sono stato co-autore del seguente lavoro 
scientifico e di due elaborati relativi a congressi : 
 
Biazzo M. et al. “Diversity of cwp loci in clinical isolates of Clostridium difficile” 
(Submitted to Journal of Medical Microbiology, 2013). 
Biazzo M. et al. Poster: “Diversity of cwp loci in clinical isolates of Clostridium 
difficile”. 3rd International Clostridium difficile Symposium, Bled – Slovenia 22 to 24 
September 2010. 
Biazzo M. et al. Poster: “Diversity of cwp loci in clinical isolates of Clostridium 
difficile”. 4th International Clostridium difficile Symposium, Bled – Slovenia 20 to 22 
September 2012. 
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ABSTRACT 
An increased incidence of Clostridium difficile infection (CDI) is associated with the 
emergence of epidemic strains characterised by high genetic diversity. Among the factors 
that may have a role in CDI there is a family of 29 paralogs, the cell wall proteins (CWPs), 
which compose the outer layer of the bacterial cell and are likely to be involved in 
colonisation. Previous studies have shown that 12 of the29 cwp genes are clustered in the 
same region, named after slpA (cwp1) the slpA locus, whereas the remaining 17 paralogs are 
distributed throughout the genome.  
The variability of 14 of these 17 cwp paralogs was determined in 40 C. difficile 
clinical isolates belonging to six of the currently prevailing PCR ribotypes. Based on 
sequence conservation, these cwp genes were divided into two groups, one comprising cwp 
loci having highly conserved sequences in all isolates, and the other 5 loci showing low 
genetic conservation between isolates of the same PCR ribotype as well as between different 
PCR ribotypes. Three conserved CWPs, Cwp16, Cwp18 and Cwp25, and two variable ones, 
Cwp26 and Cwp27, were characterised further by Western blot analysis of total cell extracts 
or S-layer preparations of the C. difficile clinical isolates. Expression of genetically invariable 
CWPs is well conserved in all isolates, while genetically variable CWPs are not always 
expressed at comparable levels even in strains containing identical sequences but belonging 
to different PCR ribotypes.  
In addition, we chose to analyse the immune response obtained in a protection 
experiment, carried out in hamsters, using a protein microarray approach to study the in vivo 
expression and the immunoreactivity of several surface proteins, including 18 Cwps. 
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1. INTRODUCTION 
 
1.1 Clostridium difficile : general features 
 
Clostridium difficile is a spore-forming, Gram-positive, obligate anaerobic bacterium 
and is the most common cause of nosocomial infectious diarrhea. It is found in the 
commensal flora of 3% of the adults and 24 % of patients in hospitals (Gould and McDonald 
2008). Since the 1970s this species is recognized as a cause of human gastrointestinal 
infection, and now is known to cause the most frequent healthcare-acquired infectious 
diarrhea in developed countries (Voth and Ballard 2005; Barbut, Gariazzo et al. 2007).  
C. difficile infection (CDI) shows different clinical symptoms, ranging from 
uncomplicated asymptomatic carriage and mild diarrhea to life-threatening toxic megacolon 
and pseudomembranous colitis (PMC) requiring surgical intervention (Barbut, Gariazzo et al. 
2007). Over the last decade the incidence of C. difficile infection has dramatically increased 
due to the emergence of new lineages (such as PCR ribotypes 027, 017 and, more recently, 
078) that are more transmissible and cause more severe infections. A thorough analysis of 
strains from different sources and geographical regions shows significant microdiversity of 
clonal complexes demonstrating the evolution of C. difficile (Cairns, Stabler et al. 2012). 
The study of this pathogen takes into account a range of selective pressures created by 
human activity and practices in healthcare settings. Typical features of CDI include: watery 
diarrhea, abdominal pain and cramps, lower quadrant tenderness, fever, leukocytosis and 
hypoalbuminemia. Re-occurrences can arise in 20% of the cases after the first episode and in 
50% after the second episode even after treatment (Barbut, Gariazzo et al. 2007). 
Infection begins with the ingestion of C. difficile spores excreted from feces of infected 
patients. Spores are easily transmitted via persons (usually hands of healthcare staff), fomites 
and air, and they persist in the environment and are transmitted to new hosts (Barbut, 
Gariazzo et al. 2007). 
C. difficile is an important nosocomial pathogen in part due to the healthcare facility 
environment containing a high number of spores from infected patients; the hospital 
environment and patients taking antibiotics develop a discrete ecosystem where C. difficile 
persists and where certain virulent clones can survive. A major risk factor for CDI is age 
(≥65 years); this is generally believed to be due to a senescence of the immune response, 
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resulting from a combination of comorbidities, immune-related changes in the fecal flora and 
normal age-related changes (Ginaldi, Loreto et al. 2001). 
In addition, alterations of the intestinal microflora allow the overgrowth of C. difficile 
caused by the consumption of broad-spectrum antibiotics, such as clindamycin, penicillins, 
cephalosporin and the flouroquinolones (Schroeder 2005; Bartlett 2008; Hookman and 
Barkin 2009). 
Other contributory factors for CDI include: gastrointestinal surgery; chemotherapeutic 
agents for cancer, for example, methotrexate and proton-pump inhibitors, all of which affect 
the gastrointestinal microflora allowing C. difficile proliferation followed by the production 
of high levels of toxin(s). Several virulence factors have been described in C. difficile such as 
flagella (Eveillard, Fourel et al. 1993), fimbriae and proteolytic enzymes (Borriello, Davies et 
al. 1990), surface layer proteins (Bianco, Fedele et al. 2011). Among these, toxins A and B 
are recognized as the major factors responsible for CDI (Voth and Ballard 2005). 
One of the preconditions for the beginning of the infection is the colonization by C. 
difficile of the host’s intestinal tract and evasion of the immune system. The organism will 
then enter the host and survive numerous pressures to compete with the flora of the 
gastrointestinal tissue, produce and secrete the major virulence factors: toxins tcdA and tcdB 
(Wright, Drudy et al. 2008) 
C. difficile produces three toxins: TcdA, TcdB and the binary toxin (CTD). Several 
studies have reported that the most important virulence factors are the two toxins A and B, 
showing that the main symptoms of infection are due only to their action (Rupnik, Wilcox et 
al. 2009). 
The genes encoding them, tcdA and tcdB, are chromosomally located along with three 
accessory genes forming the 19.6-kb pathogenicity locus (Figure 1). These are: tdcR, which 
encodes an alternative RNA polymerase sigma factor positively regulating toxin production; 
tcdC, a negative regulator of toxin production that interferes with the RNA polymerase-TcdR 
complex; and tcdE, a gene encoding a holin-like protein, involved in the release of toxins 
(Dupuy, Govind et al. 2008). 
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Figure 1 Pathogenicity Locus (PaLoc) of Clostridium difficile 630 encodes the two large clostridial  toxins TcdA 
and TcdB and the two regulatory proteins TcdR and TcdC 
 
Both toxins belong to the family of large clostridial toxins (LCT) characterized by a 
size between 260-308 kDa, by cytotoxic activity and by a common mechanism of action (von 
Eichel-Streiber, Boquet et al. 1996). 
After their release into the environment, they enter in eukaryotic cells where they act 
with a mono-O-glucosylation (of a specific threonine residue) on Rho / Ras proteins, that are 
essential for many molecular mechanisms. As all the glucosyltransferase toxins, toxin A and 
toxin B are organized into four domains "ABCD": 
A: biological activity domain 
B: receptor binding domain 
C: auto proteolitic cleavage domain 
D: delivery domain 
The domain A has glucosyltransferase activity, is at the N-terminus of the toxin and is 
the only domain of the toxin to be translocated into the cytosol of the target cell. The B 
domain, at the C terminus, is involved in binding with receptors rich in carbohydrates and is 
characterized by regions composed of repeats. The domain C, situated directly downstream 
of the glucosyltransferase domain, has a self-protease activity and is responsible for the 
processing of the toxin. The domain D is the least characterized and is thought to be involved 
in the formation of transmembrane structures, during the formation of pores and in the 
translocation of the toxin into the cytosol (Belyi and Aktories 2010) (Figure 2).  
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Figure 2. ABCD-model of clostridial glucosylating toxins. The clostridial glucosylating toxins are constructed of 
at least 4 domains. The A-domain covers the glucosyltransferase activity. The B-domain consisting of 
polypeptide repeats is involved in receptor-binding. The C-domain is responsible for the autocatalytic cleavage 
of the toxins (arrow: cleavage site) and is a cysteine-protease with the catalytic residues DHC. Lysine-600 (K) 
was shown to be involved in InsP6-binding. InsP6 is necessary for activation of the cysteine protease. The D-
domain is likely involved in the delivery of the A-domain into the cytosol. This domain contains a hydrophobic 
region (indicated) suggested to be important for insertion of the toxin into endosome membranes. 
 
 
 
 
The two toxins have different tropisms for the host cell membrane: tcdA binds the 
apical portion of the cell, while tcdB prefers to attach to its basolateral portion (Rupnik, 
Wilcox et al. 2009) (Figure 3). 
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Figure 3. C. difficile colonizes the intestine (colon) after disruption of the normal intestinal flora. To what 
extent adhesion and biofilm production are involved in the pathogenesis of C. difficile is unknown; in the 
scheme, bacterial cells are shown as free cells and attached to host cells. Toxigenic strains produce toxin A and 
toxin B (TcdA and TcdB). TcdA binds to the apical side of the cell and, after internalization, causes cytoskeletal 
changes that result in disruption of tight junctions and loosening of the epithelial barrier, in cell death or in the 
production of inflammatory mediators that attract neutrophils. Disruption of tight junctions enables both TcdA 
and TcdB to cross the epithelium. TcdB binds preferentially to the basolateral cell membrane. Both toxins are 
cytotoxic and induce the release of various immunomodulatory mediators from epithelial cells, phagocytes 
and mast cells, resulting in inflammation and the accumulation of neutrophils. In an animal model, TcdB was 
shown to have a tropism for cardiac tissue, which would require that TcdB enters the bloodstream. 
 
After endocytosis, the proteolytic activity of TcdA and TcdB leads to cleavage of the 
catalytic domain from the holotoxin, which is then transferred into the cytoplasm through a 
toxin-mediated pore. This cleavage requires only inositol phosphate from the host cell as a 
co-substrate (Rupnik, Wilcox et al. 2009). 
In the cytosol the two toxins glucosylate the small GTPase Rho and Ras superfamily 
that are involved in many cellular processes: organization of the cytoskeleton, cell motility, 
regulation of transcription, cell cycle progression and apoptosis (Belyi and Aktories 2010). 
Besides the damage caused by TcdA and TcdB,  there could be additional damage 
caused by the action of the binary toxin CDT (Popoff, Rubin et al. 1988; Goncalves, Decre et 
al. 2004). The role of this protein in pathogenesis is not yet defined, but it is known  to act 
inside the host cell by modifying the polymerization of actin through ADP-ribosylation 
(Schwan, Stecher et al. 2009; Papatheodorou, Wilczek et al. 2012). 
CDI can be treated with a limited number of agents such as metronidazole and oral 
vancomycin (Owens 2007). Newer agents such as fidaxomicin have recently been licensed, 
though more knowledge of their effects is stiil needed from clinical practice (Louie, Miller et 
al. 2011). 
The use of fecal transplantation from healthy people to patients suffering CDI is an 
additional method which has been practiced in refractory cases of CDI with the aim of 
restoring normal microbiota. Furthermore, vaccination may lead to an improvement of the 
current treatment options (Lo Vecchio and Zacur 2012). 
A variety of molecular typing approaches have been developed to study C. difficile and 
CDI including: multilocus sequence typing (MLST), multilocus variable-number tandem-
repeat analysis (MLVA), slpA gene sequence typing, amplified fragment length 
polymorphism, pulsed-field gel electrophoresis (PFGE), restriction endonuclease analysis 
(REA), toxinotyping (based on sequence data of toxins A and B) and PCR ribotyping 
(Killgore, Thompson et al. 2008). Generally, most of the methods are compatible, though 
PCR ribotyping is the most widely accepted in Europe with the Anaerobe Reference 
 
11 
 
Laboratory in Cardiff (UK) having a collection of the strains and also the role of assigning 
PCR ribotypes; more than 427 PCR ribotypes have been identified.  In North America, PFGE 
is the preferred method of typing.  
The PCR ribotyping is a typing method based on the amplification of the intergenic 
spacer region (ITS) between 16s and 23s rDNA of C. difficile. The number and length of 
ITSs vary in the genome of different C. difficile strains.  Consequently, different migrations 
patterns of migration of the PCR products are observed for different strains. Each pattern of 
migration corresponds to one PCR ribotype (Figure 4).  
 
 
Figure 4. Schematic view of the PCR ribotyping method. 
 
Alarmingly, in the past decade the emergence of a new group of highly virulent C. 
difficile strains (with PCR ribotype 027) has been reported that has caused outbreaks of 
increased disease severity in North America and Europe. In 2003 an epidemic of CDI was 
reported in southern Quebec and the Montreal district of Canada (Pepin, Valiquette et al. 
2004). 
Concurrently, a similar strain had also been isolated in several states of North America, 
and in March 2004, Stoke Mandeville Hospital (in the UK) reported a major outbreak 
including severe cases of CDI: 334 cases and 38 deaths (Cairns, Stabler et al. 2012). By 2005,  
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a considerable number of hospitals were reporting rates of CDI at five times their baseline 
rate (Loo, Poirier et al. 2005). Outbreaks in the UK, North America and Canada were found 
to be due to the dissemination of an epidemic strain subsequently identified as BI by REA, 
NAP1 by PFGE and PCR ribotype 027 by PCR ribotyping and referred to as BI/NAP1/027 
(Killgore, Thompson et al. 2008). In late 2005, other European countries documented 
outbreaks of this strain (van Steenbergen, Debast et al. 2005; Kuijper, Barbut et al. 2008; 
Bacci, St-Martin et al. 2009) and similar reports from many other countries across the globe 
including Australia (Riley, Thean et al. 2009), Korea (Tae, Jung et al. 2009), Japan (Kato, Ito 
et al. 2007), Hong Kong (Cheng, Yam et al. 2009) and Costa Rica (Quesada-Gomez, 
Rodriguez et al. 2010) were subsequently announced. Patients infected with PCR ribotype 
027 were found to have more severe diarrhea, higher mortality and more re-occurrences of 
symptoms (Borriello 1998). It has been thought that this increase in virulence and increase in 
re-occurrence rate were due to one or more of the following characteristics: exposure to 
fluoroquinolone antibiotics prior to CDI; increased production of toxin; prolonged production 
of toxin; and increased  sporulation, which in turn increases the risk of transmission. 
Exposure to the fluoroquinolone class of antibiotics has been thought to be the strongest risk 
factor for CDI with PCR ribotype 027 (McCusker, Harris et al. 2003). 
Epidemic strains of PCR ribotype 027 have been reported to produce significantly 
higher levels of toxins A and B compared with other strains (McDonald, Killgore et al. 2005). 
PCR ribotype 027 was also found to have an 18-bp deletion and a frameshift mutation due to 
a single base pair deletion at position 117 in the tcdC gene (Dupuy, Govind et al. 2008). The 
frameshift mutation results in a truncated protein and it is hypothesized that this leads to the 
deregulated expression of toxins A and B. 
Rates of CDI, most notably PCR ribotype 027 in the UK and other parts of Europe, 
appear to have declined in the last 4 years. Furthermore,  between 2007/2008 and 2010/2011, 
there was a 42.9% decrease in the number of PCR ribotype 027 strains isolated by the C. 
difficile Ribotype Network (CDRN) in the UK (Cairns, Stabler et al. 2012). This has occurred 
simultaneously with an increase in a variety of other PCR ribotypes, and now PCR ribotypes 
014, 001 and 078 represent the most prevalent strains in European hospitals, as observed in 
the last European surveillance performed in 2008 (Bauer, Notermans et al. 2011). Emergence 
of the animal-associated PCR ribotype 078 C. difficile is recognized as both a gut colonizer 
and a cause of CDI in domestic animals and livestock (Cairns, Stabler et al. 2012). PCR 
ribotype 078 isolates have been found to be the most predominant from animal species with 
CDI, most notably pigs, calves and horses (Rupnik, Widmer et al. 2008). C. difficile has also 
been found in contaminated food for human consumption, with PCR ribotype 078 being the 
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most frequently implicated (Simango and Mwakurudza 2008; Rodriguez-Palacios, Reid-
Smith et al. 2009; Songer, Trinh et al. 2009). 
Recently, a study found C. difficile in 4.8% (five out of 119) of seafood and fish 
samples from a grocery store and all toxin positive isolates were found to be PCR ribotype 
078 (Metcalf, Avery et al. 2011). 
A population-based cohort study found that community-acquired CDI affected those 
who lack the traditional risk factors such as hospitalization or antibiotic exposure, and 
patients with community-acquired CDI were also found to be younger (Khanna, Pardi et al. 
2012). The documented cases of community-acquired CDI also appear to be on the rise, and 
the increased incidence of community acquired infection with PCR ribotype 078 could be 
linked to the fact that this strain is found in both humans and animals (Cairns, Stabler et al. 
2012). In addition, with the increase in documented cases of isolation of C. difficile from 
food products for human consumption, concerns have been raised about possible 
transmission between animals and humans in the community. Although C. difficile is not a 
proven food borne pathogen, there is evidence that the same strain can cause symptomatic 
disease in both pigs and humans (Debast, van Leengoed et al. 2009). 
As PCR ribotype 027, PCR ribotype 078 has been described to be an emerging 
pathogen. 
The characterisation of the genetic conservation between strains belonging to different 
PCR ribotypes could help significantly to identify the genetic elements associated with the 
onset of CDI. It has already been established through sequencing of the genomes of a number 
of C. difficile strains of different origin that there is a high variability in gene composition 
and conservation between strains (Sebaihia, Wren et al. 2006; He, Sebaihia et al. 2010; Scaria, 
Ponnala et al. 2010). In this study, we analyse the distribution and variability of 14 cwp genes 
in 40 C. difficile clinical isolates of the 6 prevailing PCR ribotypes in Italy (Spigaglia, 
Barbanti et al. 2010) and, more generally, in Europe (Bauer et al., 2011).  
 
1.2 The “Reverse Vaccinology” approach 
Vaccines can be made from live-attenuated microbes, inactivated microorganisms, and 
purified microbial components such as polysaccharide-carrier protein conjugates. These 
approaches lead to the development of a conventional vaccine. However, they show several 
limitations. For example, immunogenic proteins are not necessarily protective antigens, often 
have a variable sequence and they are difficult to produce and/or purify on a large scale, 
leading to high production costs. In addition, the antigens chosen are only the most abundant 
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and not all of them can be analysed simultaneously. As a consequence these traditional 
approaches have failed against several infectious diseases and, thus, vaccines have not yet 
been developed. 
Bioinformatics and whole-genome sequencing of bacteria brought innovation to the 
vaccinology field, identifying potential vaccine candidates without the need to grow the 
pathogen. This approach, named ‘reverse vaccinology’ (Rappuoli 2000), reduces the time and 
cost of new vaccine identification also for those diseases for which conventional approaches 
have failed (Mora, Veggi et al. 2003). Scientists can now search for the potential surface 
protein sequences using various algorithms. This new approach allows systematic 
identification of all the potential antigens of a pathogen in order to develop a safe and 
efficacious vaccine against any infectious disease. 
After the genes coding for the pathogen proteins have been identified, they are cloned 
in E. coli, expressed and the corresponding proteins purified. Purified proteins are then used 
to immunize mice and the sera analysed in order to verify their predicted exposure and ability 
to trigger an immune response. Protective antigens are analysed again in vitro using 
opsonophagocytosis and bactericidal assays with the aim of final antigen selection. Potential 
candidates can also be determined on the basis of sequence conservation among different 
strains of the pathogen (Figure 5).  
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Figure 5. Approaches to vaccine development. Schematic demonstration of the essential steps required for 
vaccine development using the conventional approach (a), and reverse vaccinology (b). (Johri, Paoletti et al. 
2006) 
 
The sequencing of a bacterial genome gives the possibility to discover novel antigens 
missed by conventional vaccinology methodologies. The reverse vaccinology approach was 
first used to identify antigens for the development of a vaccine against serogroup B 
meningococcus (Mora, Veggi et al. 2003). The use of multi-genome sequence information 
for vaccine design represented a major change from the common concept that a single 
genome sequence is sufficient to produce a potential vaccine candidate. A single genomic 
sequence is not sufficient to represent the variability of bacterial populations. Therefore, 
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multiple sequences might be needed for a vaccine formulation that is effective in the case of a 
highly differentiated species. This is common to many important bacterial pathogens and this 
observation is in the context of the pan-genome reverse vaccinology era (Mora, Donati et al. 
2006). Thus a universal vaccine can be obtained by using a combination of antigens chosen 
from different strains and not only a single one. However, their selection should consider the 
population structure of the microorganism, giving importance to each representative strain in 
the epidemiology of the disease. 
The next step in order to reach a more comprehensive picture of bacterial populations 
will be population vaccinology. Vaccines will be then formulated from a collection of 
proteins that, together, protect against the major circulating populations of a pathogen. In 
addition, the sequencing of human and pathogen genomes has provided large amounts of data 
relevant to the study of human immune responses and complex host–pathogen interactions. 
Using and ameliorating immuno-informatic tools, such as T-cell and B-cell epitope-mapping 
algorithms, and of structure-oriented bioinformatics (Arcus, Lott et al. 2006; De Groot 2006) 
will lead to the refinement of the totally synthetic vaccine design containing strings of the 
best epitopes encoded by the microorganism (Figure 6). 
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Figure 6 Flow chart for antigen discovery and refinement of the search. Three major genome-based 
approaches are involved in the identification of new potential vaccine candidates: (a) analysis of a single 
genome sequence in order to select secreted or extra-cellular proteins to identify potential vaccine candidates, 
(b) comparison of multiple genomes of the same species to assess intra-species diversity, (c) population 
genomics to achieve a more comprehensive coverage against the major circulating species. These three steps 
lead to (d) population vaccinology, which takes into account antigen variability and population structure, (e) 
allowing a more rational design of a new generation of vaccine targets, and (f) in silico screening, such as 
epitope-mapping and structure-oriented bioinformatics, will enble refinement of  the search (Mora, Donati et 
al. 2006). 
 
In the case of C. difficile, 300 proteins have been identified as potential antigens by a 
reverse vaccinology approach based on sequence analysis of the genome of 10 different 
strains. Among these 300 putative antigens, a major group of proteins belonging to the same 
family is represented by the cell wall binding proteins or CWPs.  
In this study, we analyse the distribution and variability of cwp genes using two 
approaches. We have analysed the distribution of 14 cwp genes in 40 clinical isolates and 
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their conservation with respect to strain 630, we then focused on the characterisation of the in 
vitro expression of Cwp proteins (by Western blots) and also on the analysis of expression of 
Cwp proteins in vivo using a protein microarray approach. 
 
1.3 The cell wall proteins 
One of the main components of the bacterial surface is the S-layer, a protein structure 
that forms a regular two-dimensional network on the whole surface of the bacterium and  is 
present in many prokaryotes (Calabi, Ward et al. 2001). The S-layer is involved in virulence 
also in the case of other human pathogens (McCoubrey and Poxton 2001; Eidhin, Ryan et al. 
2006).  However, although the proteins that consitute the S-layer belong to the same protein 
family, between different species such proteins have a low or no similarity of sequence 
(Fagan, Albesa-Jove et al. 2009). 
The S-layer completely covers the surface of the bacterium and, acting as an adhesin, 
facilitates the bacteria-host cell interaction (Fagan, Albesa-Jove et al. 2009). 
The S-layer described for the first time in C. difficile by Kawata et al., in 1984, consists 
of two proteins of different molecular weight, which associate to form a solid complex 
(Fagan, Albesa-Jove et al. 2009). The molecular weight of the two subunits varies depending 
on the strain: the larger of the two proteins may vary from 48 to 56 kDa, whereas  the smaller 
varies from 37 to 45 kDa (McCoubrey and Poxton 2001; Eidhin, Ryan et al. 2006). 
These proteins are encoded by the slpA gene as a single precursor. After a post 
translational cleavage of this precursor two mature proteins are produced, the HMW (high 
molecular weight) SLP and the LMW (low molecular weight) SLP (Figure 7). The SLPs 
facilitate adhesion to cultured cell lines and the LMW SLP is an immunodominant antigen 
(Calabi, Ward et al. 2001). 
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Figure 7. The precursor protein SlpA showing the cleavage sites generating the signal peptide (_) and the 
mature HMW SLP and LMW SLP (_). 
 
This is the first reported example in which the two S-layer proteins are derived from a 
single gene product and not by the expression of two separate genes (Calabi, Ward et al. 
2001). The precursor, responding to a signal sequence, is conducted through the cytoplasmic 
membrane to be processed into two proteins: the high molecular weight (HMW) SLP and the 
low molecular weight (LMW) SLP (Calabi and Fairweather 2002). 
These proteins are generated by posttranslational cleavage of the precursor SlpA by the 
cysteine protease Cwp84 (de la Riva, Willing et al. 2011). The two subunits are positioned in 
such a way that the HMW, facing the interior, acts as an anchor for the LMW exposed to the 
external environment (Fagan, Albesa-Jove et al. 2009) (Figure 8). 
 
Figure 8. Model of orientation of the subunits of the S-layer. The HMW SLP is shown interacting with the cell 
wall through one region of the protein; however, the extent and exact nature of this interaction is currently 
unknown. The LMW SLP interacts, through the interaction domain, with the HMW and is directed towards the 
external environment (Fagan, Albesa-Jove et al. 2009).  
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After analysing several strains, the LMW-SLP shows high sequence variability (Fagan, 
Albesa-Jove et al. 2009). This finding can be explained by considering the position of this 
subunit. In fact, the exposure to the external environment and the marked variability of 
LMW-SLP represent a strategy to escape the host immune system (Fagan, Albesa-Jove et al. 
2009). 
Furthermore, a TBLAST analysis of the genome of strain 630 with the amino acid 
sequence of SlpA, revealed sequence homology between the HMW SLP and 28 other gene 
products, 11 located in the same locus of the slpA gene and 17 in other regions of the genome 
(Calabi et al. 2001). These 28 genes encode the cell wall proteins. The slpA locus of strain 
630 is 36,661 bp long and includes 18 ORFs. Among these, only 12 ORFs, distributed both 
downstream and upstream of the slpA gene, code for Cwps (Calabi, Ward et al. 2001) (Figure 
9). 
 
Figure 9. Arrangement of predicted ORFs upstream and downstream of the C. difficile 630 slpA gene. All ORFs 
are transcribed in the same direction (left to right), and the size of each protein is proportional to the size of 
the box. The regions of proteins shaded in black indicate where sequence homology is found with N-acetyl 
muramoyl-L-alanine amidase, and those not shaded where sequence homology is lacking. Proteins indicated 
by hatched shading are unrelated to N-acetyl muramoyl-L-alanine amidase. 
 
Further analysis shows a significant sequence homology of HMW SLP with the family 
of autolysin of Bacillus subtilis, in particular with proteins LytCB and LytC. The latter is the 
main autolysin of B. subtilis and has an N-acetyl muramoyl-L-alanine amidase activity, 
involved in the destruction of the peptidoglycan. Although the involvement of these proteins 
in cell adhesion has been verified, the specific function has not yet been identified (Sebaihia, 
Wren et al. 2006). 
Several of the cwp genes are not conserved in all the C. difficile genomes characterised 
so far. In general, 12 of the 29 cwp genes are clustered in the same region of the genome, 
named after slpA (cwp1) the slpA locus (Calabi, Ward et al. 2001; Karjalainen, Waligora-
Dupriet et al. 2001), whereas the remaining 17 paralogs are distributed throughout the 
genome. We focused our study on the genes coding for the latter group of CWPs since they 
are poorly characterised.  
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Knowledge of the conservation of these genes in clinical isolates would offer useful 
information for the characterisation of the role that CWPs may have in C.difficile infection 
and also provide another tool for classifying newly emerging strains. 
To date, 29 cwp genes have been identified in C. difficile which code for a family of 
cell wall proteins involved in colonisation and pathogenesis. All of these CWPs have a 
conserved domain containing two or three copies of the Pfam 04122 motif, a putative cell 
wall binding repeat 2 (Fagan, Janoir et al. 2011)(Figure 10). 
 
Figure 10. Schematic representation of the domain composition of the 29 CWPs of C. difficile. 
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In addition, several of the CWPs show a second, more variable domain that may 
specify a unique function. Fagan et al., in 2009 suggested a model of the cell surface of C. 
difficile in which the continuous film of the S-layer is located above the peptidoglycan and is 
interrupted in several points by Cwps (Figure 11). 
 
 
 
Figure 11. The two SLPs are shown above the peptidoglycan layer: the HMW SLP (red), the LMW SLP (blue). 
Other minor cell wall proteins are shown as two-lobed structures ; the filled areas, indicating domains 
predicted to be exposed to the environment, are variable between these proteins. Putative cell wall polymers 
(Ganeshapillai, Vinogradov et al. 2008) including putative lipid-containing polymers (Poxton and Cartmill 1982) 
are shown as vertical orange bars. 
 
To better define the structure of the cell surface of C. difficile, the results of the studies 
by Davies and Borriello need to be taken into account. In 1990, they showed that many 
strains of C. difficile produced the capsule and that the genome of strain 630 contains a 
cluster of genes involved in the synthesis of extracellular polysaccharides (Davies and 
Borriello 1990; Sebaihia, Wren et al. 2006). 
Current knowledge of the molecular basis of pathogenesis is limited primarily to the 
activities and regulation of two major toxins. In contrast, little is known about the 
mechanisms involved in colonization of the enteric system and the role of CWPs. 
Some members of the CWP family have been investigated extensively. Among these, 
Cwp84 is a protease that cleaves the SlpA precursor and also degrades many proteins of the 
host cell extracellular matrix, Cwp66, which acts as an adhesin, and CwpV, a protein that is 
expressed in a phase variable manner (Emerson, Reynolds et al. 2009). 
De la Riva et al. in 2011 compared the phenotypes of C. difficile strains containing 
insertional mutations in either cwp84 or its paralog cwp13. They showed that the presence of 
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uncleaved SlpA in the cell wall of the cwp84 mutant resulted in aberrant retention of other 
cell wall proteins at the cell surface. The cwp13 mutant cleaved the SlpA precursor normally 
and had a wild-type-like colony phenotype. Both Cwp84 and Cwp13 are produced as 
proenzymes which are processed by cleavage to produce mature enzymes. In the case of 
Cwp84, this cleavage does not appear to be autocatalytic, whereas in Cwp13 autocatalysis 
was demonstrated (De la Riva, Willing et al. 2011). Cwp13 appears to have a role in the 
processing of Cwp84, but is not essential for Cwp84 activity. Cwp13 cleaves SlpA in the 
HMW SLP domain, and De la Riva suggested it may reflect a role in cleavage and 
degradation of misfolded proteins at the cell surface (Figure 12). 
 
 
 
 
 
 
Figure 12 Model for processing and activities of Cwp84 and Cwp13. SlpA, Cwp84, and Cwp13 are produced as 
preproteins containing signal peptides that are removed during processing by the sec system (step a). The 
propeptides of Cwp84 and Cwp13 are removed (step b), either by autocatalysis in the case of Cwp13 or by an 
unknown activity together with Cwp13 activity in the case of Cwp84, to form the active enzyme species that 
are incorporated into the S-layer (step c). Mature Cwp84 cleaves the SlpA precursor (step d), which results in 
the formation of the H/L complex (step e). Misfolded proteins are recognized by Cwp13 and are cleaved in 
their cell wall binding domains to prevent incorporation into the S-layer, resulting in detachment from the cell 
and deposition into the growth medium (step f). S-L, S-layer; PG, peptidoglycan; Mem, membrane;Cyt, 
cytoplasm (de la Riva, Willing et al. 2011). 
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CwpV is the largest member of the CWPs family and is expressed in a phase variable 
manner (Reynolds, Emerson et al. 2011). Reynolds et al., in 2011 showed that CwpV 
promotes C. difficile aggregation, mediated by the C-terminal repetitive domain. CwpV is 
post-translationally cleaved at a conserved site leading to formation of a complex of cleavage 
products (like the SlpA processing). The highly conserved N-terminus anchors the CwpV 
complex to the cell surface (Figure 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.Cartoon representation of the overall model for post-translational CwpV processing and 
incorporation into the S-layer with analogy to SlpA processing.  *,cleavage sites. Step 1, signal peptide (SP) 
cleavage and transport across the cell membrane. Step 2, cleavage of protein. SlpA is cleaved by Cwp84 into 
the LMW and HMW SLP. The protease responsible for CwpV cleavage is currently unknown. Step 3, formation 
of a complex of the products of cleavage, anchoring both products to the cell surface (Reynolds, Emerson et al. 
2011). 
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Protein translocation across the cytoplasmic membrane is an essential process in all 
bacteria. The Sec system, comprising at its core an ATPase, SecA, and a membrane channel, 
SecYEG, is responsible for the majority of this protein transport (Driessen and Nouwen 
2008). Recently, a second parallel Sec system has been described in a number of Gram-
positive species (Bensing and Sullam 2002; Lenz and Portnoy 2002; Chen, Wu et al. 2004; 
Siboo, Chaffin et al. 2008). This accessory Sec system is characterized by the presence of a 
second copy of the energizing ATPase, SecA2, and, in the systems studied, is responsible for 
the translocation of a subset of Sec substrates.  
In common with many pathogenic Gram-positive species, C. difficile possesses two 
copies of SecA. Fagan and Fairweather in 2011 described the first characterization of the C. 
difficile accessory Sec system and the identification of its major substrates, that are SlpA, 
Cwp2, CwpV, Cwp66 and Cwp84. Furthermore, they showed that expression of either 
dominant negative allele or antisense RNA knock-down of SecA1 or SecA2 dramatically 
impaired growth, indicating that both Sec systems are essential for C. difficile (Fagan and 
Fairweather 2011). 
In this study 18 cell wall proteins have been selected for further characterization using 
a protein microarray analysis of the immune response obtained in a protection experiment 
carried out in hamsters. Briefly, hamsters were vaccinated with various domains of Toxin A 
(p5 /6) and Toxin B and then challenged with a lethal dose of C. difficile strains 630 or B1. 
Only animals that developed protective immunity would survive the lethal challenge. We 
have used the sera from protected and from control animals to identify antigens capable of 
eliciting a specific immune response towards C. difficile toxins and surface proteins.  
Microarray technology has been a valuable approach to screen potential antigens useful 
for developing vaccines against C. difficile. Microarrays were implemented for the 
identification of the most immunogenic antigens and profiling of disease-specific antibody 
response to identify surface protein exposed during infection.  
 
1.4 The Protein Microarray Technology 
Traditionally, the properties of proteins have been elucidated by studying single 
molecules, one experiment at a time. Since this process is slow and labour intensive, in the 
last decade high-throughput methods have been developed in order to analyse a large number 
of molecules, such as DNA, proteins or metabolites simultaneously in a single experiment. In 
particular, DNA microarrays are a valuable tool in genomic research (Schena, Shalon et al. 
1995). They have been used for several applications: gene expression patterns, location of 
transcription factor binding sites and detection of sequence mutations and deletions on a large 
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scale (Hall, Ptacek et al. 2007). However, DNA microarrays are only informative of the 
genes themselves and provide little knowledge regarding the protein functions they encode. 
More recently, the application of high-throughput approaches has been extended to protein 
studies. These include profiling with mass spectrometry (Gavin, Bosche et al. 2002; Ho, 
Gruhler et al. 2002; Gavin, Aloy et al. 2006) and protein microarrays (MacBeath and 
Schreiber 2000; Zhu, Bilgin et al. 2001). 
Microarray technology allows the simultaneous analysis of many samples within a 
single experiment. The whole field of protein microarray technology has received 
considerable impetus as a result of the increasing genomic information available. New 
technologies such as automated protein expression and purification systems, used for the 
generation of capture molecules, and the need for analysis of whole ‘proteomes’ will be a 
driving force for fast developments within the field of protein microarray technology.  
Protein chips have emerged as a new approach for a variety of applications including 
the identification of protein-protein interactions, protein-phospholipid interactions, small 
molecule targets, and substrates of protein kinases or of other enzyme families (Winssinger, 
Ficarro et al. 2002). 
They can also be used for clinical diagnostics and to monitor diseases  (Hall, Ptacek et 
al. 2007). Typically, protein chips are prepared by immobilizing proteins on a treated 
microscope slide using a contact spotter (MacBeath and Schreiber 2000; Zhu, Bilgin et al. 
2001) or a non-contact microarrayer that applies capillaries or inkjet technology to deposit 
nanolitre–picolitre droplets onto the surface of the slide (Delehanty 2004; Jones, Gordus et al. 
2006). 
Proteins must remain in a wet environment. For this reason, the printing process is 
carried out in a humidity-controlled environment and the proteins are exposed to samples 
containing the corresponding binding molecules in solution. Different slide surfaces can be 
used for protein chips. When choosing a slide surface, the proteins should be immobilized on 
the chip maintaining their conformation and  functionality, thus achieving maximum binding 
capacity (Zhu, Bilgin et al. 2003). Proteins can be oriented either randomly or uniformly on 
the slide surface. They can be attached randomly through amines, aldehyde- and epoxy-
derivatized glass surfaces (Kusnezow, Jacob et al. 2003). Coating the glass surface with 
nitrocellulose, gel pads, or poly-L-lysine also leads to a random orientation as the proteins are 
passively adsorbed onto the surface (Angenendt, Glokler et al. 2002; Charles, Goldman et al. 
2004).  Reactive proteins can be located on a proteome chip with small molecule probes 
coupled to either fluorescent, affinity, photochemical, or radioisotope tags. Fluorescent labels 
are generally preferred as they are safe, effective and are compatible with readily available 
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microarray laser scanners. Antibodies are the most prominent capture molecules used to 
identify targets.  Selectivity of the capture molecules is the most crucial issue in the context 
of all array-based proteomic approaches. 
Protein chips are used in a wide range of applications; they have been used to unravel 
the functions of previously uncharacterized proteins and to discover new functions for known 
proteins. Proteome chips have been used to study protein-protein interactions (Zhu, Bilgin et 
al. 2001), protein-DNA interactions (Hall, Zhu et al. 2004), protein-lipid interactions (Zhu, 
Bilgin et al. 2001), protein-drug interactions (Huang, Zhu et al. 2004), protein-receptor 
interactions (Jones, Gordus et al. 2006), and antigen-antibody interactions (Michaud, Salcius 
et al. 2003). These microarrays could be used to study protein–protein interactions on a 
genome-wide scale, many known interactions could be confirmed and a set of novel binding 
proteins could be detected (Figure 14). Experiments designed to detect protein–lipid 
interactions have shown that the identification of proteins able to bind low molecular weight 
compounds is possible. This opens the possibility to examine an entire proteome directly for 
protein–drug interactions. Microarray immunoassays are of general interest also for all 
diagnostic applications where several parameters of one sample have to be analysed in 
parallel (Mendoza, McQuary et al. 1999; Schweitzer, Wiltshire et al. 2000). 
In addition, proteome chips have been used to study kinase activities (Ptacek, Devgan 
et al. 2005) and serum profiling (Zhu, Hu et al. 2006). Proteomic research and diagnostic 
applications will be the two major fields addressed by protein microarray technologies. In 
medical research, protein microarrays will accelerate immune diagnostics significantly by 
analysing in parallel all relevant diagnostic parameters of interest. The reduction of sample 
volume is of great importance for all applications in which only minimal amounts of samples 
are available. One example might be the analysis of multiple tumour markers from a 
minimum amount of biopsy material. 
Proteome chips have also been used successfully to screen patient’s sera for the 
presence of autoantibodies (Kattah, Alemi et al. 2006) or viral specific antibodies (Zhu et al., 
2006). Thus proteome chip technology is a valuable high-throughput method for probing a 
group of proteins for a specific function or property. It is an exceptional new way to discover 
unknown proteins, as well as new functions of already known proteins. 
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Figure 14 Applications of functional protein microarrays. A representative sample of the different assays that 
have been performed on functional protein microarrays. Proteins are immobilized at high spatial density on a 
microscope slide and the slide can then be probed for various interactions. While Cy5 is the fluorophore 
shown, many other fluorophores can be used for detection (Hall, Ptacek et al. 2007). 
 
The growing field of protein microarray technology also requires the development of 
methods for high-throughput generation of recombinant proteins. Such methods are a 
prerequisite for the growing demand for thousands of specific capture molecules. In addition 
to their use in the generation and isolation of appropriate capture molecules, recombinant 
proteins will be used to generate microarrays that allow a rapid and efficient screening for 
high-affinity binders with minimal, or no, cross-reactivity to other proteins.  
Detection of captured targets is performed by laser scanners with confocal detection 
optics (Templin, Stoll et al. 2002). Readout systems based on different techniques such as 
fluorescence, chemiluminescence or radioactivity can be used to detect complex formation 
within each spot (Figure 15).  
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Figure 15. Schematisation of the protein microarray technique.  
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New trends in technology, mainly in nanotechnology and microfluidics, newly 
established detection systems and improvements in computer technology and bioinformatics 
have been rapidly integrated into the development of microarray-based assay systems. 
Microarrays built from tens of thousands of different probes per square centimetre, are now 
well established high-throughput hybridization systems that generate huge sets of data within 
a single experiment. 
Accurate quantification with protein microarrays can be achieved by including positive 
and negative control spots and/or internal calibration spots. Hence, this will lead to robust 
and reliable diagnostic assays.  
 
2. Materials and Methods 
        2.1 Bacterial strains and growth conditions  
C. difficile clinical isolates collected by the Istituto Superiore di Sanità, Italy (1987-
2010) were used in this study (Table 1). Strains were isolated from symptomatic patients in 
13 different Italian hospitals. In particular, strains C192, C193, C252, C253, AR1, AR2, TR2, 
TR3, An45 and An56 were isolated during five different outbreaks that occurred in hospitals 
C, D, E, F and G. C. difficile isolates were typed as PCR ribotype 001 (two isolates), 012 (ten 
isolates), 014 (two isolates), 018 (ten isolates), 078 (ten isolates) and 126 (six isolates). 
Strains were cultured at 37°C under anaerobic conditions on Brucella agar plates containing 
vitamin K1 (0.5 mg/ml), haemin (5 mg/ml) and 5% defibrinated sheep red blood cells or in 
brain heart infusion (BHI) broth (Difco Laboratories). C. difficile strains 630, R20291 and 
M120 were used as control strains for PCR ribotype 012, 027 and 078/126, respectively. C. 
difficile 630 was obtained from the University of Paris-Sud, Chatenay Malabry, France. C. 
difficile strains R20291 and M120 were obtained from the Microbial Pathogenesis 
Laboratory, Pathogen Genomics, Wellcome Trust Sanger Institute, Hinxton, United Kingdom. 
 
The E. coli strains were grown in LB or HTMC medium. 
- LB (Luria Bertani broth) 
Composition: 10 g/L Trypton, 5 g/L Yeast extract, 10 g/L NaCl  pH 7.6; 100 μg/ml 
ampicillin  
- HTCM (High Throughput Complex Medium) 
Composition: 15 g/L Glycerol (or Glucose); 0.5 g/L MgSO4 (2mM); 30 g/L yeast 
extract (Difco); 16 g/L K2HPO4; 6 g/L KH2PO4; 200 μg/ml ampicillin; pH 7.35 
-BHI (Brain Heart Infusion Broth) 
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Composition: 17.5 g/L Brain Heart Infusion, 10 g/L Enzymatic Digest of Gelatin, 2 g/L 
Dextrose, 5 g/L NaCl, 2.5 g/L Na2HPO4 , pH 7.4 ± 0.2 at 25°C 
-Brucella agar plates: 
Composition: 39 g/L Columbia Agar Base (OXOID), 5 g/L Yeast extract (OXOID). 0.5 
mg/ml vitamin K1, 5 mg/ml haemin and 5% defibrinated sheep red blood cells 
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Table 1. Clostridium difficile clinical isolates analysed in this study 
  
Isolate Year Origin§ TcdA TcdB Binary toxin Toxinotype PCR ribotype 
F III 10 2005 A + + - 0 001 
IT0843 EU 2008 B + + - 0 001 
C192 1987 C + + - 0 012 
C193 1987 C + + - 0 012 
C252 1987 D + + - 0 012 
C253 1987 D + + - 0 012 
AR1 1987 E + + - 0 012 
AR2 1987 E + + - 0 012 
TR2 1989 F + + - 0 012 
TR3 1989 F + + - 0 012 
An45 1989 G + + - 0 012 
An56 1989 G + + - 0 012 
F II 3 2005 H + + - 0 014 
IT0855 EU 2008 D + + - 0 014 
IT0603 2006 A + + - 0 018 
IT0707 2007 A + + - 0 018 
IT0807 2008 I + + - 0 018 
IT0808 2008 I + + - 0 018 
IT0825 2008 L + + - 0 018 
IT0829 2008 L + + - 0 018 
IT0839 EU 2008 B + + - 0 018 
IT0840 EU 2008 B + + - 0 018 
IT0926 2009 M + + - 0 018 
IT0929 2009 M + + - 0 018 
CD5 1998 H + + + 5 078 
IT0810 2008 I + + + 5 078 
IT0834 2008 I + + + 5 078 
IT0901 2009 N + + + 5 078 
IT0909 2009 O + + + 5 078 
IT0918 2009 I + + + 5 078 
IT0919 2009 I + + + 5 078 
IT0925 2009 M + + + 5 078 
IT0936 2009 M + + + 5 078 
IT1003 2010 D + + + 5 078 
1991 2001 H + + + 5 126 
2350 2002 H + + + 5 126 
3360 2006 H + + + 5 126 
IT0820 2008 L + + + 5 126 
IT0824 2008 L + + + 5 126 
IT0846 EU 2008 I + + + 5 126 
§ Strains were isolated at 13 Italian hospitals (arbitrarily denominated A to O). 
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2.2 Cloning and expression of Clostridium difficile recombinant proteins 
C. difficile ORFs were PCR-amplified using chromosomal DNA of strain 630 as a 
template. PCR products were cloned into a modified pET15b
+
 expression vector (Novagen) 
using the PIPE cloning method (Figure 16) (Klock, Koesema et al. 2008). The PCR-
amplified vector (vector PCR, V-PCR) and the PCR-amplified ORFs (insert PCR, I-PCR) 
were mixed and used to transform the E. coli HK100 strain (Klock, White et al. 2005). 
 
Figure 16. The pET-15b vector carries an N-terminal His-Tag sequence followed by a thrombin site and three 
cloning sites. Unique sites are shown on the circular map. Note that the sequence is numbered by the pBR322 
convention, so the T7 expression region is reversed on the circular map. The cloning/expression region of the 
coding strand transcribed by T7 RNA polymerase is shown in panel B.  
A 
B 
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In order to reduce the number of transformants carrying the empty pET15b
+
 vector, 
used as V-PCR template, pET15b+ was modified by cloning the toxic CcdB gene into it 
using the PIPE technique. The CcdB-Chloramphenicol cassette was excised from the 
SpeedET vector (Klock, Koesema et al. 2008) and cloned into pET15b
+
 using the permissive 
E. coli strain DB3.1. After PCR colony screening and plasmid sequencing, a DB3.1 clone 
containing the correct pET15b-CcdB/cm construct was selected and used to amplify and 
purify the plasmid that was then used as DNA template for the V-PCR. The oligonucleotide 
primers used to prepare the V-PCR and the 15 bases at the 5’ ends of the primers used to 
prepare the I-PCRs were designed in such a way that a Tobacco Etch Virus (TEV) cleavage 
site was introduced between the vector sequence coding for the N-term hexa-histidine tag and 
the ORF sequence. The forward and the reverse oligonucleotides used to obtain the V-PCR 
were 5’-TAACGCGACTTAATTCTAGCATAACCCCTTGGGGCCTCAAACGG-3’ and 
5’G C C C T G G A A G T A C A G G T T T T C G T G A T G A T G A T G A T G A T G G C T G
C T G C C C A T G G T A T A T C - 3 ’  respectively. The forward and reverse 15 base long 5’ 
tails of the oligonucleotides used to obtain the I-PCRs were 5’-CTGTACTTCCAGGGC-3’ 
and 5’-AATTAAGTCGCGTTA-3’, respectively. 2 μl of V-PCR were mixed with 2 μl of 
each I-PCR and 3 μl of these mixtures were used to transform Ca2+ competent HK100 cells. 
Transformants were then selected by PCR screening and DNA sequencing of the plasmids 
extracted from the PCR-positive clones. In order to express cloned ORFs, the plasmids were 
prepared from the positive clones in HK100 and used to transform Ca
2+
-competent BL21-
DE3T1r (New England Biolabs) or the T7 Express competent E. coli cells (New England 
Biolabs). The new clones were screened for expression of the heterologous proteins. The 
wells of 96 deep well plates containing 1.5 ml of LB medium with the addition of 100 μg/ml 
ampicillin were inoculated with the expression clones and grown at 37 °C up to OD600 nm= 
0.5. Protein expression was then induced by adding 1 mM IPTG and incubating the culture at 
the same temperature for an additional 3 h. To check protein expression and solubility, the 
induced cells were lysed with B-Per buffer (Pierce, Rockford, ILU.S.A.) using the 
manufacturer’s instructions. The results were evaluated by analysing total and soluble protein 
extracts in SDS-PAGE.  
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2.3 Clostridium difficile DNA isolation, amplification and sequencing. 
Genomic DNA was isolated by a standard protocol for Gram-positive bacteria using a 
NucleoBond AX-G kit (Macherey-Nagel) according to the manufacturer’s instructions. 
Genes were amplified using primers specific for regions external to each ORF and are listed 
in Table 3. Only for cwpV were primers designed for amplifying a conserved internal 
segment (904 bp) of the otherwise highly variable coding region (Emerson, Reynolds et al. 
2009). When primers were used in a multiplex PCR reaction, the two sets were added at 
different concentrations: 1 μM and 0.3 μM for primers specific for the longer gene and the 
shorter gene, respectively. DNA amplification was performed using 1 μl of purified genomic 
DNA (50 ng) in a final volume of 50 μl. The nucleotide sequences of PCR products were 
determined using a BigDye Terminator V3.1 kit (Applied Biosystem) in an ABI PRISM 3700 
Analyzer (Applied Biosystems). The nucleotide sequences have been submitted to the 
GenBank database under accession numbers JQ389122-JQ389476. 
2.4 Sequence alignments and phylogenetic analysis. 
The percentage of sequence identity was calculated by pair wise BLAST with the 
VECTOR NTI SUITE 11 (Informax, Bethesda), with gaps included. Sequence alignments 
were performed using CLUSTAL W (1.83, GCG Wisconsin Package version 11.1) and 
phylogenetic trees were inferred by the neighbour-joining-distance-based method and 
bootstrapped 1,000 times. 
2.5 Protein expression. 
 
 C. difficile protein extraction 
 
Total protein and S-layer extracts 
The preparation of whole cell lysates was obtained from cultures grown in BHI broth to 
stationary phase (OD600 nm ≈ 1) by a method based on a freeze-thaw procedure (Fagan and 
Fairweather 2011). Briefly, cultures of C. difficile were harvested by centrifugation at 5,000 x 
g for 10 min at 4°C and the pellets frozen at -20°C. Bacteria were thawed, suspended in PBS 
to an OD600 nm = 20 and incubated at 37°C for 10 min. Three such freeze-thaw cycles were 
carried out in order to obtain consistent and reproducible lysis. 
The extraction of S-layer was performed following a previously described method 
(Fagan and Fairweather 2010).  
To obtain S-layer-associated proteins of C. difficile strains, bacteria were grown in a 50 
ml BHI broth for 16-18 h, harvested by centrifugation at 3500 x g for 10 minutes and washed 
 
36 
 
in 5 ml of PBS. Cells were re-suspended in 0.5 ml (1\100 starting culture) of 0.2 M Glycine, 
pH 2.2 plus protease inhibitors (Complete Mini EDTA-free, Roche) and digestion was 
allowed to proceed for 20 min at room temperature with gentle agitation. Then the bacterial 
suspension was transferred to microfuge tubes and harvested by centrifugation at 3500 x g for 
10 minutes at 4°C. The supernatant, which contains the surface proteins, was recovered and 
the pH was modified by the addition of 2 M Tris base to achieve a pH in the range of 7–8.  
For SDS-PAGE and Western blot analysis, 3.5 µl of each total cell extract and 5 µl of 
each S-layer extract were used.  
 
Extraction of Flagella 
 
C. difficile strains were inoculated in Falcon tubes containing 2 ml of BHI. Tubes were 
incubated overnight in an anaerobic hood. 250 µl of each culture were plated onto 4 plates.  
After incubation overnight, the colonies were collected from the plates with a loop and re-
suspended in 500 µl of H2O.  All the samples were mixed by vortexing for 3 min in 500 µl of 
H2O and centrifuged for 5 min at 13000 rpm at 4°C. The supernatant containing the flagella 
was transferred to a clean tube and used for SDS-PAGE analysis. 
 
    Expression of recombinant His-tagged proteins 
 
Selected clones were first grown in 25 ml LB medium with 100 µg/ml ampicillin 
overnight at 37°C with agitation at 180 rpm. The starter culture was then diluted to 500 ml of 
the same growth medium in a 2-liter flask and grown at 30°C with agitation at 180 rpm. 
When the culture reached an O.D.600 nm value ranging from 0.4 to 0.7, 1 mM IPTG (final 
concentration) was added for induction of expression. The culture was incubated at 25°C for 
3.5 h with agitation at 180 rpm.  
 
 Protein expression using HTFS (High Throughput Fermentation System) 
This system is based on in-house adapted 50 ml Falcon tubes, prepared by boring three 
round holes in the cap: one in the centre for air intake and two lateral exit holes. The air 
intake hosts a 2 ml Falcon pipette connected to a fluximeter and the air exit is filtered by two 
shortened ART1000 filtered tips (Figure 17). Selected clones were then grown in 4 ml 
Glucose-HTCM at 37°C with agitation until bacteria reached the exponential phase. Thirty 
five microliters of each culture were inoculated into a solution containing 35 ml of Glycerol-
HTCM and 50 µl PPC (poly propylene carbonate anti-foam solution, 1/10 diluted) in a 
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Falcon tube. The Falcon tubes were placed on a heater set to 26.1°C (to keep the temperature 
from dropping under 26°C) and air flux (which also provides agitation) was set to 3 VVM 
(volume gas / [volume liquid / minute]). The bacteria were grown for 36 h, then the Falcon 
tube caps are replaced with new ones and tubes were centrifuged at 4000 x g at 4°C for 40 
min. Supernatants were discarded and pellets were stored at -20°C. 
 
Figure 17. HTFS machinery has been developed in house at the Novartis Vaccines Fermentation Lab, by Erwin 
Swennen and colleagues. The system is composed of 2 block heaters holding a maximum number of 24 
standard 50 ml Falcon tubes with 3 holes manually drilled in the cap. Filtered ART1000 tips are used as air-exits 
and the central hole is attached to a fluximeter set to 3 VVM  
 
2.6  Protein purification. 
 Poly-Prep Column His-Tagged protein purification 
Pellets were thawed at room temperature and resuspended in 10 ml B-PER buffer 
(Bacterial- Protein Extraction Reagent, Pierce) containing 20 μl of 50 mM MgCl2, 100μl 
DNAse I (100 K units Sigma D-4263) in PBS, 1 mg/ml lysozyme (Sigma L-7651) in PBS. 
Lysis solution was transferred to 50 ml centrifuge tubes, kept at room temperature for 40 
min, vortexed a few times and then centrifuged at 40000 g for 25 min. Poly-Prep columns 
were prepared and equilibrated with 1 ml Ni-Activated Chelating Sepharose Fast Flow in 50 
mM phosphate buffer and 300 mM NaCl at pH 8 before the supernatant was loaded. Column 
flow-through was discarded. Ten milliliters of 20 mM imidazole, 50 mM phosphate, 300 mM 
NaCl buffer at pH 8 were added to remove impurities.  
Proteins bound to the column were eluted with 4.5 ml of 250 mM imidazole, 50 mM 
phosphate, 300 mM NaCl buffer at pH 8 and collected in three 1.5 ml fractions. 15μl of 200 
mM DTT (Dithiothreitol) (2mM final concentration) were added to each fraction. Protein 
concentration of each fraction was estimated by the Bradford assay and 10 μg of each protein 
sample were loaded onto an SDS-PAGE gel. Proteins were then stored at 4°C. Poly-Prep 
Column GST-Tagged protein purification pellets were thawed at room temperature and 
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resuspended in 10 ml B-PER buffer (Bacterial-Protein Extraction Reagent, Pierce), 20 μl of 
50 mM MgCl2, 100 μl DNAse I (100 K units Sigma D-4263) in PBS, 1 mg/ml lysozyme 
(Sigma L-7651). Lysis solution was transferred to 50 ml centrifuge tubes, kept at room 
temperature for 40 min, vortexed a few times and then centrifuged at 40000 x g for 25 min. 
Poly-Prep columns were prepared, equilibrated with 0.5 ml Glutathione-Sepharose 4B, 
washed with 2 ml H2O and 10 ml PBS, pH 7.4 before loading the supernatant. Column flow-
through was discarded. 10 ml of PBS, pH 7.4 was added to remove impurities. Proteins 
bound to the column were eluted with 50 mM TRIS and 10 mM reduced glutathione at pH 8 
and collected in three 1.5 ml fractions. 2 mM DTT was added to each fraction. Protein 
concentration of each fraction was estimated by the Bradford assay and 10 μg of each protein 
sample were loaded onto an SDS-PAGE gel.  
 
2.7  SDS-PAGE and immunoblotting.  
 Extracts were separated by SDS-PAGE in a 12% polyacrylamide gel, followed by 
Western blotting and immunodetection with specific antibodies. Antisera against Cwp16, 
Cwp18, Cwp25, Cwp26 and Cwp27 were raised in mice immunised with purified 
recombinant CWPs obtained by overexpressing the corresponding ORFs of C. difficile strain 
630 using the pET15b
+
 vector (Novagen) and the E. coli strain BL21(DE3) (Invitrogen) 
expression system. Primary antibodies, used at a 1:2,000 dilution in blocking buffer, were 
detected using horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G 
(1:20,000; Invitrogen) and the SuperSignal West Pico chemiluminescent substrate (Thermo 
Scientific Pierce). A marker for direct visualization of standard bands (MagicMark XP 
Western Protein Standard, Invitrogen) was used routinely for protein molecular mass 
estimation directly on Western blots.  
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2.8  Protein microarray 
 Design 
A total of 89 proteins were selected among those predicted, or known, to be secreted or 
surface exposed in C. difficile. Designing the chip layout is a key step in microarray-based 
research to overcome some limitations of the technique. For this experiment, we have 
designed a layout  with four replicates of each protein (Figure 18). The same layout was then 
printed four times within the same slide, in order to obtain a microarray with a total of 16 
replicates of each protein. The core of the Arrayjet technology, the JetSpyder, enables the 
inkjet print head to be simultaneously primed with multiple samples for microarray printing.  
The design also included various types of controls, mostly serial dilutions of control 
proteins or immunoglobulins (at a concentration ranging from 0.008 to 0.5 mg/ml). A 
solution of 40% glycerol in PBS (PBS-Gly) buffer was spotted in at least twice the number of 
the protein spots and used to detect non-specific signals caused by cross-contamination 
during spotting (Figure 18).  
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Figure 18 Microarray layout. Spots of C. difficile surface proteins are represented by white boxes, PBS_Gly 
buffer spots are highlighted in blue.  
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 Preparation and Spotting 
 
Purified C. difficile proteins were dialyzed in PBS with the Slide-A-Lyzer Dialysis 
Cassette system (Thermo Scientific) and diluted to obtain a concentration of 0.5 mg/ml.  
Each protein solution was then transferred to two 384-well polypropylene microplates 
(15 μl/well). The plates contained serial dilutions, ranging from 0.5 mg/ml to 0.016 mg/ml, of 
seven controls: Human IgG, Human IgM, Human IgA, Mouse IgG, Hamster IgG, Cy3 and 
Cy5-labelled BSA (Amersham Biosciences) and biotin-labelled BSA. All samples were 
spotted onto nitrocellulose-coated slides by using the Arrayjet Marathon Microarrayer.  
The Arrayjet Marathon Microarrayer transfers samples of biological liquids from 
microplates onto microarray slides. The samples are transferred by means of an inkjet print 
head and a patented JetSpyderTM. The JetSpyderTM allows 12 or 32 samples to be drawn 
from wells into the print head as follows: the print head is purged with clean buffer liquid 
(50% water, 50% glycerol and 0.05% Triton X100); the print head picks up the JetSpider, 
which is then purged with buffer via the print head; the Jet Spider, with 12 capillaries 
projecting downwards in a 4x3 array at 9 mm spacing, or 32 in a 8x4 array at 4.5 mm 
spacing, is lowered into a microtitre plate. Samples are drawn from the wells via the 
JetSpyder into the nozzles of the print head; the JetSpider is returned to its cleaning station; 
the print head prints the slides and the cycle is repeated until all the samples in the plates are 
printed. The Jet Spider draws 0.7 µl of sample and each nozzle prints 0.1 nl/spot (0.05 ng of 
protein/spot) for a final spot diameter of 90–100 μm. 
The wells must be filled to a level adequate for the planned printing, and must not 
contain dirt or air bubbles. Centrifuging the plates at 3000 rpm for 5 minutes should remove 
bubbles, but the plates should be inspected and re-centrifuged if necessary. The software 
allows the user to specify a print run; initialise the instrument; load plates and slides; perform 
the print run; unload trays and slides; and shut down the instrument. The software will 
produce a GAL file describing the mapping of the contents of the wells onto spots on the 
slides. The GAL file is needed to map the positions of the samples in the plates to the 
positions of the corresponding spots on the slides. 
 Hybridization and Staining 
The slides were washed with PBS at 20°C for 5 min and then with PBS-T (0.05% 
Tween 20 in PBS) at 20°C for 1 min followed by 1 h incubation in the dark with shaking in 
Protein Blocking Buffer (Whatman code: 10485356). Slides were incubated with 100 µl of 
hamster sera diluted 1:300 in Protein Blocking Buffer for 1 h at 25°C in the dark with 
shaking and then washed 3 times (at 25°C, 5 min each time) with PBS-T. Anti-hamster 
IgG/Alexa Fluor647 secondary antibody (Invitrogen, cod.A21451) at a 1:800 dilution in 
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Protein Array Blocking buffer, was added and incubation prolonged for 1 h at 25°C in the 
dark with shaking.  Only in the last slide (00282619) an Anti-hamster IgG/Cy3 (abcam, code: 
ab6969), diluted 1:800 in Protein Array Blocking Buffer was added.  Slides were washed 
twice with PBS-T (25°C, 5 min each time), once with PBS (25°C, 10 min), and once with 
sterile milliQ H2O (25°C, 30 sec).  Slides were removed from the incubation chamber, 
washed once with sterile milliQ H2O and dried with nitrogen. 
An example of the scheme used for a hybridization experiment of the 8 hamster sera 
analysed in this work is given below 
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 Data collection 
 
The fluorescence signals were detected using a high resolution laser scanner 
PowerScanner™ (Tecan) to detect the specific fluorophore used, with 0.1% laser intensity 
and 300% of gain for all the slides, except for the last slide (00282619) in which a 0.1% laser 
intensity and 90% of gain were used.  
The signal was then quantified with the program ImaGene 9.0 (Biodiscovery Inc, CA, 
USA). The data collected were analysed using the in-house developed program "Protein 
Chip". The mean fluorescence intensity (MFI) of each spot was calculated as an average 
fluorescence intensity of  the 16 replicates, minus the background fluorescence intensity. To 
determine specific binding of an antibody-probe to a recombinant protein, a mean 
fluorescence intensity value of 2000 was established as the threshold for scoring positive 
results. Average intensities of fluorescence below this value were scored as negative. 
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3. RESULTS 
3.1 Sequence conservation of cwp genes 
Sequence alignment of ORFs predicted to code for CWPs in published C. difficile 
genomes (Table 2) was used to identify conserved flanking regions suitable for designing 
primers for the amplification of the corresponding cwp ORFs. 
 
Table 2. List of published C. difficile genomes, available until 2011. 
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Among the public genomes, we selected three fully sequenced genomes  to use as 
reference in our analysis. The genomes chosen correspond to the strains 630, R20291 (SM) 
and M120. Strain 630 (ribotype 012) is multi-drug resistant, and was isolated from a patient 
with severe pseudomembranous colitis that had spread to dozens of other patients in the same 
ward in Zurich, Switzerland in 1982. Subsequently, strain 630 has become the most widely 
used strain in the laboratory. The strain R20291 (SM) was isolated in the UK in 2006. This 
strain (PCR ribotype 027) is characterised by high level fluoroquinolone resistance, hyper-
production of the pathogenic toxins A and B and  has been implicated in the increase of 
incidence, recurrence and mortality of C. difficile associated disease (CDAD) in hospitalised 
patients. The strain M120, a PCR ribotype 078 strain, was isolated from an Irish diarrheic 
patient in 2007. The PCR ribotype 078 strains are generally those most frequently present in 
domestic animals.  
Twelve of the 29 cwp genes encoding the cell wall proteins are clustered in the same 
region of the genome, named after slpA (cwp1) the slpA locus (Calabi, Ward et al. 2001; 
Karjalainen, Waligora-Dupriet et al. 2001), whereas the remaining 17 paralogs are distributed 
throughout the genome (Figure 19). We conducted our analysis on all genes not included in 
the slpA locus, as this locus is already been characterized by other groups (Karjalainen, 
Saumier et al. 2002; Eidhin, Ryan et al. 2006; Kirby, Ahern et al. 2009; Chapeton Montes, 
Collignon et al. 2013). 
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Figure 19.Distribution of cwp genes in the genome of C.difficile. Genes in pink represent the genes  analysed in 
our study. Only the 17 cwp ORFs not included in the slpA locus were taken into consideration. 
 
 In several cases only one of the two flanking regions was conserved in all the 
published genomes. In these cases, different sets of primers were designed that would allow 
the amplification of the corresponding ORF in all the known variants of the locus. A list of 
the primers used is given in Table 3.  
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Table 3.Oligonucleotides used in this study 
  
Oligonucleotide    Sequence (5’-3’) 
cwp13-for AAGGGGGAGAAAGCGTGAAAA 
cwp13-rev AAACTTATACTACATAAATTTAAAGCTG 
cwp13-for1 GTCCAACAAAAAGTTTTAATACAAATC 
cwp13-rev1 GATATATTTAAGCTTTTTAATTGTTGTTC 
cwp13-for2 GTATATTTGTAAATACTTGATATTTAGTC 
cwp15-for1 CTTAATAGGTGGAACTTCTGTATTAA 
cwp15-rev2 ATCATCTATAACTACATCATCCAC 
cwp16-for GGCAATAAATGATATAGTGAAGATAA 
cwp16-rev TAATTACATTCTTATCTTATAGCTTTAGT 
cwp16-for1 GAAAAATGGTTCAGATAAGGTAG 
cwp17-for GGGTTAGATACACTTTGACATATT 
cwp17-rev CAAATGTACATACAGTCTTACTATTG 
cwp17-for1 GAAACAGCAGTTAAAATAAGTAAAGA 
cwp18-for GCTATATCATTCTTTATAAGTCAAGC 
cwp18-rev CTATATTGAAATATAACTTAGTTTACTTG 
cwp19-for TACACTTGATTACAAAATGCATATAG 
cwp19-rev TACACTTGATTACAAAATGCATATAG 
cwp19-for1 ACCCAGGTTTACCAGAAGTTA 
cwp19-rev1 CAAGTAAAGTTATTTTAATTGGAGGA 
cwp20-for ATTATTAAAAAGGGAAAGAGGTAATG 
cwp20-rev GTCATAGAGCTATGGGAGCTA 
cwp20-for1 GTTATATAAAAAGCTATACTTATAAAAGC 
cwp20-for2 GAGTATCTGGTATGTCATTTACTAA 
cwp20-rev1 GATGCAGTAAGCATTGGAGCT 
cwp22-for AAGATTCATGGAGATGGCAAAG 
cwp22-rev GCTTTTATTGATTGAATTTCACATCT 
cwp24-for AGCGTAGATGTAATACTATGTTA 
cwp24-rev GAAATTGGAAAAATCAAAACCATTCC 
cwp25-for CCTTTTATGGAGAAAGAAGGTATT 
cwp25-rev CTTATCTCCATTTGATAGCCTC 
cwp26-for ATAATTTAGGTGAAAATATTTAAGAGAAG 
cwp26-for1 GAAAAAATAGAGTGGACACCTCATT 
cwp26-rev ATGAACTCCACTCTATAGATTGTA 
cwp27-for GTGACAAAATTTTGAAATATAAACTAATTTC 
cwp27-rev GAAACATAAAATTTTAATACTTATCGTC 
cwp28-for GCAATTTTACATAAGTTTGTTAAGTAC 
cwp28-rev CCTCCTAGTTAATTTCTTATATTACAC 
cwp29-for GGAGGAAAAGAAAATTTAATGTAGAAT 
cwp29-rev GAGACATTTACATACCACATAGT 
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All the sets of primers whose sequence was highly conserved in all published genomes 
or, alternatively, could discriminate for the presence/absence of a specific cwp gene were 
combined as two sets in a multiplex PCR reaction and tested on control genomic DNAs 
extracted from strains 630, R20291 and M120. With this approach, amplification of a 
conserved PCR fragment becomes a positive control for the negative result obtained when 
using primers specific for genomic regions that are not present in all published genomes 
(Figure 20).  
 
 
 
 
 
 
Figure 20. . Results from duplex PCR amplification of loci cwp13 and cwp29 performed on the clinical 
isolates of Table1 
 
PCR fragments of the expected length were obtained with all sets of primers, except for 
those designed for the amplification of cwp14, cwp21 and cwp23. Hence, these genes were 
excluded from our analysis that was focused on the remaining 14 cwp genes listed in Figure 
22. Amplification of the corresponding 14 cwp ORFs was carried out on genomic DNA 
extracted from 40 strains isolated from patients at 13 Italian hospitals and representative of 
the 6 PCR ribotypes prevalent in Italy (Table 1). The nucleotide sequence was then 
determined for all of the PCR fragments obtained (Figure 21).  
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Figure 21 Distribution of the 14 cwp genes in 40 Italian clinical isolates and their conservation with respect to 
strain 630. Reference strains are highlighted in the blue box. Strains also tested for expression of a specific 
Cwp by Western blot analysis are indicated by a full circle (●) when found positive or by an open circle (O) 
when a specific band could not be detected. 
 
In total, 511 ORFs were sequenced and analysed for sequence conservation using the 
multiple alignment program Clustal W (Chenna, Sugawara et al. 2003). The ORFs were 
found to be conserved in all 40 isolates for eight of the cwp genes analysed, while the 
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remaining six cwp ORFs were absent or, when present, not conserved in at least one of the 
clinical isolates. In particular, cwp27 and cwp29 were absent in all the PCR ribotypes 
078/126 isolates as already reported for M120, the reference strain for PCR ribotype 078 (He, 
Sebaihia et al. 2010). Similarly, the ten PCR ribotype 018 strains of our collection lack 
cwp28, while in the same isolates the other 13 cwp genes were found to be present and 
conserved (Figure 21). A PCR fragment of the expected length for cwp17 was obtained in all 
isolates except for two, one PCR ribotype 078, which lacks also cwp16, and one PCR 
ribotype 126 strain.  
Moreover, the sequence of cwp17 in all the remaining isolates of PCR ribotype 078 and 
126 showed a lower level of conservation with respect to strain 630 than the isolates of the 
other PCR ribotypes. Finally, the cwp26 gene was found to be alternatively absent/present 
but variable or conserved in different isolates of the same PCR ribotype with the exception of 
the ten PCR ribotype 018 isolates, which all shared identical cwp26 sequences. The number 
of single nucleotide polymorphisms (SNPs) found in each cwp gene among the various PCR 
ribotypes with respect to the ortholog sequence in strain 630 and the corresponding amino 
acid substitutions are reported in Table 4. 
 
Table 4.Gene variability in 14 cwp genes of Clostridium difficile. The sequence determined in a representative 
clinical isolate for each PCR ribotype was compared to the equivalent sequence in strain 630 by measuring the 
number of SNPs and amino acid substitutions observed. 
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The sequences of the 14 cwp ORFs in one isolate for each PCR ribotype, arbitrarily 
selected as representative of all strains that belong to the same PCR ribotype, were joined in a 
single string and compared with the corresponding cwp sequences of strain 630, also joined 
in a string.  
The phylogenetic tree inferred from the sequences of the 14 cwp loci among the clinical 
isolates and constructed by the use of the neighbour-joining algorithm is shown in Figure 22. 
Two interesting observations can be drawn from this analysis. First, strains that belong to 
PCR ribotypes 078 and 126 always have identical cwp sequences in the clinical isolates of 
our collection. Conversely, the reference strain for PCR ribotype 078 M120 and strain QCD-
23M63, another PCR ribotype 078 strain whose genome sequence has been characterised 
(Forgetta, Oughton et al. 2011), show some variability for these cwp genes (Figure 23). 
Second, the two PCR ribotypes 078 and 126 are clearly more closely related to the 
hypervirulent PCR ribotype 027 than to any of the other PCR ribotypes analysed in our study. 
. 
 
 
 
Figure 22.Phylogenetic tree, rooted on C. difficile strain 630, of cwp sequences among C. difficile clinical 
isolates. The tree was constructed from the sequence results inferred from 14 cwp gene sequences by using 
the neighbour-joining algorithm. Bootstrap confidence values for each node of the tree were calculated over 
100 replicate trees (only bootstrap values >80% are indicated). The number of nucleotides representing all 
polymorphisms found in each PCR ribotype is given in parentheses. 
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3.2 Analysis of in vitro expression of Cwp proteins 
Five of the CWPs under study were characterised further by Western blot analysis of 
total cell extracts or S-layer preparations of the C.difficile clinical isolates. Three conserved 
CWPs, Cwp16, Cwp18 and Cwp25, and two variable ones, Cwp26 and Cwp27, were selected 
for this analysis since antisera showing high specificity for these Cwps were available. For 
simplicity, total cell extracts were prepared from only one representative isolate for each PCR 
ribotype as well as from any strain showing variable alleles. A similar mode of expression 
was detected in total extracts of all the clinical isolates analysed for the highly conserved 
cwp16, cwp18 and cwp25 genes (Figure 23).  
 
Figure 23. Analysis of expression of conserved CWPs. Western blot analysis of total cell extracts of C. difficile 
reference strains (630, R20291 and M120) and clinical isolates representing different PCR ribotypes using anti-
Cwp16, anti-Cwp18 and anti-Cwp25 antibodies. A marker for direct visualization of standard bands 
(MagicMark XP Western Protein Standard, Invitrogen) was used for protein molecular mass assessment 
directly on Western blots. 
  
Cwp16 mature form:71.1 kDa 
Cwp18 mature form:34.7kDa 
Cwp25 mature form:31 kDa 
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However, it is noteworthy that strain IT0901, the only isolate from which we were not 
able to amplify the cwp16 gene, shows a Cwp16-positive band of the same intensity and 
molecular mass as all the other strains. This suggests that the cwp16 flanking regions that we 
used to design the primers are not conserved in strain IT0901. Moreover, since we were also 
not able to amplify the adjacent cwp17 gene in this isolate, we propose that in strain IT0901 
the entire region may contain some degree of sequence variability that does not compromise 
expression of Cwp16. For this reason, we believe Cwp16 could be included in the group of 
the highly conserved CWPs, thus bringing to 9 the number of conserved CWPs versus 5 
variable ones. In the literature there is a paucity of information on Cwps. To date, only SlpA, 
CwpV, Cwp84 and Cwp13 have been characterised.  The main aspect that they all have in 
common is that they are processed through a complex pathway before exposure on the 
bacterial surface. We believe that Cwp 16 is subjected to the same processing, as a band is 
visible at a lower molecular weight in all the samples. 
Conversely, analysis of the data obtained on expression of Cwp26 revealed that a 
protein of the expected molecular mass (49 kDa) is present in total cell extracts of the 027 
reference strain R20291 and the PCR ribotype 001 strains, but missing in the remaining 
isolates (Figure 24 A). A weaker band visible at approximately 31 kDa in all samples, 
representing a cross-reaction of the Cwp26-specific polyclonal antibody with Cwp25 (data 
not shown), was used as a sample loading control for the Cwp26-negative samples. To verify 
if the absence of Cwp26 in total cell extracts was due to the sample preparation procedure or 
to differences in expression/localisation, the Western blot analysis was repeated on S-layer 
preparations of the same strains. S-layer extracts showed the presence of a 49 kDa Cwp26-
positive band in the PCR ribotype 078 and 126 strains as well as in the 027 and 001 isolates 
already found to be positive in total cell extracts (Figure 24 B). 
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Figure 24. Expression of Cwp26. Western blot analysis of C. difficile reference strains (630, R20291 and M120) 
and clinical isolates representing different PCR ribotypes using anti-Cwp26 antibodies. Total cell extracts (A) 
and S-layer extracts (B) were separated by SDS-PAGE, followed by Western blotting with Cwp26-specific 
antibodies. A marker for direct visualization of standard bands (MagicMark XP Western Protein Standard, 
Invitrogen) was used for protein molecular mass assessment directly on Western blots. The grey arrow 
indicates the position of the expected molecular mass for the mature form of Cwp26, while the white arrow 
indicates the Cwp26-positive band at approximately 70 kDa. 
 
Likewise, the strains that belong to the PCR ribotypes 012, 014 and 018 showed a 
strong positive signal only in S-layer preparations, though the strong band recognised in these 
strains has a significantly higher molecular mass (approx. 70 kDa) than that predicted from 
the cwp26 gene sequence (Figure 24B). In addition, it should be noted that the same strong 
signal at 70 kDa is also visible in S-layer preparations of the two 012 isolates, TR2 and TR3, 
that were found cwp26-negative by PCR analysis (Figure 21). Of the other two cwp26-
negative isolates reported in Figure 1, strain CD5 displayed two positive bands at 48 and 49 
kDa, while strain F II 3 did not show any specific band recognised by the anti-Cwp26 
antibodies (Figure 24 B). Although we cannot offer an explanation for the results obtained in 
isolates TR2, TR3 and CD5, it can be inferred that F II 3 is the only strain that clearly does 
not contain a cwp26 ortholog. The results of the Western blot analysis of the expression of 
Cwp27 are shown in Figure 25.  
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Figure 25. Expression of Cwp27. Western blot analysis of C. difficile reference strains (630, R20291 and M120) 
and clinical isolates representing different PCR ribotypes using anti-Cwp27 antibodies. Total cell extracts (A) 
and S-layer extracts (B) were separated by SDS-PAGE, followed by Western blotting with Cwp27-specific 
antibodies. A marker for direct visualization of standard bands (MagicMark XP Western Protein Standard, 
Invitrogen) was used for protein molecular mass assessment directly on Western blots. 
 
Two bands of the expected molecular mass for the mature form (38 kDa) and precursor 
(41 kDa) of Cwp27, as inferred from the Cwp27 sequence analysis using the PSORT (Nakai 
and Horton 1999) and VECTOR NTI prediction programs, were seen in total extracts as well 
as in S-layer preparations of the two reference strains 630 and R20291 used as positive 
controls. Conversely, no band was visible in M120, a strain that does not have a cwp27 
ortholog.  
In clinical isolates of PCR ribotype 012, 014 and 018 the same two bands were present 
with the same intensity ratio in S-layer extracts but with varying intensities in total cell 
extracts. However, both the PCR ribotype 001 isolates of our collection, which contain a 
conserved cwp27 gene, did not show any positive signal; thus indicating that these strains do 
not express Cwp27 at detectable levels in our conditions. On the contrary, the lack of a 
positive signal in PCR ribotype 078 and 126 isolates confirms the absence of a cwp27 
ortholog in these strains. 
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3.3 Analysis of in vivo expression by Protein Microarray 
Reverse Vaccinology highlights how antigens that confer a broad range of protective 
antibody responses are highly expressed surface-exposed proteins, usually secreted as toxins 
or virulence factors well conserved among the pathogen strains. The identification of 
antigens able to confer protective immunity can be achieved with several approaches. In this 
study, we chose to analyse the immune response obtained in a protection experiment, carried 
out in hamsters, using a protein chip approach. Briefly, hamsters were vaccinated with 
various domains of Toxin A (p5 /6) and Toxin B and then challenged with a lethal dose of C. 
difficile strains 630 or B1. We have used the sera from protected and from control animals to 
identify antigens capable of eliciting a specific immune response towards C. difficile toxins 
and surface proteins. Putative antigens or proteins predicted to be secreted or surface exposed 
by genomic and proteomic approaches were purified in a His-tagged form, and used to 
generate protein microarrays on nitrocellulose-coated slides. Approximately 80 proteins were 
selected by using a combined in silico and proteomic approach (Table 5). 
Table 5. List of proteins spotted onto the chip. 
Tube N° Name note 
1 A 16 small His  ToxA+ToxB_1 
2 B4 His  ToxA+ToxB_2 
3 Chimera 9 His  ToxA+ToxB_3 
4 Chimera 12 His ToxA+ToxB_4 
5 N-G-BB His  N-G-BB His  
6 PTA2 His ToxA_1 
7 Tox A-B2 His   ToxA_2 
8 Tox A-GT-WT ToxA_3 
9 Tox A-GT-M2  ToxA_4 
10 Tox A-GT-M3 ToxA_5 
11 Tox B-GT His   ToxB_1 
12 Tox B1 His   ToxB_2 
13 Tox B4 His    ToxB_3 
14 ToxB4 ToxB_4 
15 FliC_630 FliC_630 (native) 
16 FliC_SM FliC_SM (native) 
17 FliC_001 FliC_001 (native) 
18 FliC_014 FliC_014 (native) 
19 FliC_018 FliC_018 (native) 
20 FliC_078 FliC_078 (native) 
21 FliC_126 FliC_126 (native) 
22 HMW_630 HMW_630 (native) 
23 HMW_SM HMW_SM (native) 
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24 DIF 2 His  
Leader present, peptidoglycan catabolic process, putative cell 
wall protein (no lpxtg) 
25 Dif 14 B His (domain) flagellar cap protein FliD family 
26 DIF 15 His  No leader, PSORT:extracellular, flagellar protein 
27 DIF 16 His   Lipoprotein leader 
28 20f30-563 His   Leader present, lpxtg present, cna_B domains 
29 20f560-975 His   Leader present, lpxtg present, cna_B domains 
30 DIF SleC His  SleC His  
31 DIF 40 His   Leader present, fimbrial protein 
32 DIF 44 His   Leader present, cell wall-binding domain cwp25 
33 DIF 51 His   Lipoprotein signal 
34 DIF 52 His   Leader present, bruttina, lpxtg like signal present 
35 Dif 53 His   cwp18 
36 Dif 55 His   putative cell wall hydrolase 
37 DIF 75A His  Leader present, cell wall binding domain present cwp20 
38 Dif 89 His   Lipoprotein signal 
39 Dif 104 His Lipoprotein signal 
40 Dif 106C cwp24 
41 DIF 109B His  No leader, PSORT:extracellular 
42 DIF 114 His   Lipoprotein signal 
43  Dif 130 His   Lipoprotein signal 
44  Dif 139 His   cwp14  
45 Dif 144 His   cwp7 
46 Dif 145 His   cwp6 
47 Dif 146 His   cwp5  
48 Dif 149 His   cwp11 
49 Dif 167 His   Leader present 
50 Dif 170 His   Leader present, NLPC_P60 domain 
51 
DIF 171 A His   Leader present, lpxtg like motif, cna_B domains, 95% identity 
with DIF20 
52 
DIF 171 B His   Leader present, lpxtg like motif, cna_B domains, 95% identity 
with DIF20 
53 Dif 173 His   Leader present 
54 Dif 184 His No leader, collagen binding protein 
55 Dif 187 His   cwp27 
56 Dif 189 A His   Leader present, cw binding domains cwpV 
57 
Dif 189 A (dominio)  Leader present, cw binding domains cwpV 
58 Dif 189 B His   Leader present, cw binding domains cwpV 
59 DIF 192 His   Leader present, cw binding domains cwp16 
60 Dif 194 His   Signaling protein 
61 DIF 196 His   Leader present, cw binding domains cwp13 
62 Dif 201His   cwp29 
63 Dif 204 His   cwp66  
64 Dif 205A   SlpA (from 630) recombinant 
65 DIF 207 His Leader present, cw binding domains cwp10 
66 DIF 208A His   Leader present, lpxtg like motif, cna_B domains 
67 DIF 208B His   Leader present, lpxtg like motif, cna_B domains 
68 DIF 210 His   Leader present, lpxtg like motif 
69 DIF 211 His   Leader present, cw binding domains cwp21 
70 DIF 212 His  Leader present, lpxtg like motif 
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71 DIF 225 His   Leader present, lpxtg like motif 
72 Dif 227 His   Leader present 
73 DIF 231 His   Leader present, lpxtg like motif 
74 DIF 232 His   Leader present, lpxtg like motif 
75 Dif 234 His   Lipoprotein signal 
76 Dif 327A His   SlpA (from SM) recombinant 
77 Dif 340 His Leader present 
      
78 DIF 12 His Leader present , NLPC_P60 domain, sh3 domain (CD0183) 
79 DIF 153  leader present (CD2830) 
80 DIF 183 His Lipoprotein signal (CD3669) 
81 DIF192 dominio 1 His Leader present, cw binding domains cwp16 
82 DIF208 His Leader present, lpxtg like motif, cna_B domains 
83 DIF210 dominio1 His Leader present, lpxtg like motif 
84 DIF 251His Leader present, lpxtg like protein (CD1858) 
85 CD0855   lipoprotein 
86 CD0873  lipoprotein 
87 CD1653   lipoprotein 
88 CD2029   lipoprotein 
89 CD2672  lipoprotein 
 
All of the selected proteins belong to the C. difficile strain 630, except for Dif 327A, 
HMW_SM and FliC-SM that belong to the strain R20291. Among the proteins selected for 
this screening 14 are fragments of toxins A and B, representing different domains of the two 
toxins. 
The mature form of each C. difficile protein was overexpressed in E. coli as an N-
terminal His-tag fusion protein and purified from the bacterial soluble fraction. After 
purification, the proteins were printed onto nitrocellulose-coated glass slides in sixteen 
replicates. 
Serial dilutions of Biotinylated Bovine Serum Albumin (BSA), Cy3/Cy5-labeled BSA, 
Mouse, Human and Hamster IgG were also spotted on each array as controls for fluorophore-
conjugated secondary antibodies, and for the behaviour of every pin on each printed slide 
during the spotting session. Proteins were spotted onto nitrocellulose-coated slides with the 
Arrayjet spotter.  
Hamster IgGs (HaIgG) were also spotted onto the array at 5 serial dilutions 
(concentrations from 0.008 to 0.5 mg/ml) and used as detection and calibration controls. 
Validation of the experimental conditions used for detecting protein-antibody recognition 
was obtained by observing that the Ha-IgG values of Mean Fluorescence Intensities (MFI) of 
HaIgG spots, detected after exposure with Alexa Fluor647-conjugated secondary antibody, 
were fitted best by sigmoid curves (Figure 26).  
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Other samples were printed onto the array and used as controls for spotting and 
detection. These included PBS–Glycerol buffer, which was used to detect protein carryover 
during spotting and for setting the background value, and NN-His extract (cell extract of E. 
coli not expressing any C. difficile genes), which were used to detect aspecific signals. 
On the basis of the results of the validation experiments, we arbitrarily set as a 
constraint for scoring a positive result as a real recognition, in a scale of MFI from 0 to 
65000, a value greater than 2000 MFI. 
To identify antigens recognised by the hamster sera, each serum was hybridized to the 
microarray and antigen recognition was detected with fluorophore-labelled secondary 
antibodies, Anti-hamster IgG/Alexa Fluor647 (Invitrogen, cod.A21451) or Anti-hamster 
HaIgG
0,004
mg/ml
HaIgG
0,008
mg/ml
HaIgG
0,016
mg/ml
HaIgG
0,032
mg/ml
HaIgG
0,064
mg/ml
HaIgG
0,125
mg/ml
HaIgG
0,25
mg/ml
HaIgG
0,5
mg/ml
serum 1 80 567 2002 6000 12559 27446 57576 64823
serum 2 84 662 2473 7199 15103 33632 61499 64803
serum 3 97 658 2406 6941 14279 30797 60266 64940
0
10000
20000
30000
40000
50000
60000
70000
M
FI
 
Calibration curves 
Figure 26. Graphic representation of the Ha-IgG control curves. On the x axis are indicated the different Ha-
IgG concentrations, MFI values are reported on the y axis and the continuous line correspond to the 
interpolated resulting curve. The figure is the graphic representation of the distribution of MFI values 
measured after incubation with Alexa Fluor647-conjugated secondary antibody. 
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IgG/cy3 (Abcam, code: ab6969). All the incubation steps were conducted under agitation 
using the HS 4800 hybridization station (TECAN). 
The arrays were incubated with the hamster sera reported in Table 6 
 
 
Table 6. Sera obtained from hamsters in protection experiments. 
 
 
 
 
There were two sera (number 2 and 5) obtained from control hamsters infected with C. 
difficile without previous vaccination. Also, when more than one hamster was used for a 
specific immunization/infection scheme, the sera of hamsters belonging to the same group 
were pooled prior to hybridization to the protein arrays. 
Table 7 reports the MFI values obtained for all the protein spots. Overall, 39 samples, 
which include 7 different CWP proteins, showed MFI values higher than 2000 and were 
scored as positive. MFI values reported in Table 6 have already been normalised by 
subtracting the value of the negative control (NNHis). 
 
serum 
infecting 
strain 
immunization hamster clinical outcome 
1 (negative control) ------ ------ Not infected  ------ 
2 630 no vaccine H9 died 
3 630 p5/6 + ToxB-B H1-H6 survived + diarrhea 
4 630 p5/6 + ToxB-GT H1-H6  No diarrhea 
5 B1 no vaccine H9-H10 died 
6 B1 p5/6 + ToxB-B H2-H6 survived + diarrhea 
7 B1 p5/6 + ToxB-B + ToxB-GT H2 died 
8 B1 p5/6 + ToxB-B + ToxB-GT H1,H3-H6 survived + diarrhea 
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Table 7. MFI values obtained after incubation with hamster sera. 
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The results obtained specifically for the toxin A and B fragments are presented in 
Figure 2. These data clearly show that the highest MFI values were observed with sera from 
vaccinated hamsters while, as expected, the sera from hamsters infected without a previous 
vaccination displayed very low values. The toxins that show the highest MFI values are 
ToxB4, ToxA-B2 His and ToxB1 (Figure 27). 
 
 
 
 
When comparing the values observed for the toxins with those of proteins not used for 
vaccination (Figure 28), it is noted that there was a good level of recognition by a number of 
sera with several surface proteins: Dif15, Dif75A, Dif212. Similar results were obtained also 
for three CWPs (particularly with sera 7 and 8): CwpV and Cwp21. 
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Figure 27. Protein microarray results obtained specifically for the toxin A and B fragments. 
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The same proteins gave different results when using the hamster sera obtained from 
non-vaccinated infected hamsters (Figure 29). In fact, with these sera MFI values are very 
low for all the proteins. The serum that showed higher values was the serum (number 4) from 
the hamster that was challenged with strain B1. However, it should also be noted that the 
results obtained with serum 2 (hamster not vaccinated and not infected) are above our 
threshold (2000 MFI) for several of the spotted proteins.  
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Figure 28. Comparison between values observed for the toxins with those of proteins not used for 
vaccination. In this figure are shown the results obtained with sera from all vaccinated hamsters. 
 
 
64 
 
Hence, we will consider as positive only values that are at least two-fold higher than 
those obtained for the same samples from the serum 9 “negative control”. Based on this 
consideration, the proteins that we can postulate as being expressed in vivo at levels 
sufficiently high to elicit a good immune response are: ToxA-GT, Dif104, Cwp21, CwpV, 
Cwp10.   
 
 
 
 
To demonstrate the reproducibility of the results obtained, we repeated the 
hybridization experiment with the serum 3 sample changing only the method of detection. In 
particular, a secondary anti-hamster Cy3-conjugated antibody was used instead of the Alexa 
Fluor 647-labelled antibody used in previous experiments. The results obtained (Figure 30) 
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Figure 29 .Comparison between values observed for the toxins with those of proteins not used for 
vaccination. In this figure are shown the results obtained with sera from all non-vaccinated hamsters 
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are similar, and the differences are possibly due to a generally less intense emission when 
using the Cy3 fluorophore. 
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Figure 30. Comparison between values observed for serum 3 and two 
different secondary antibodies : Alexa Fluor 647 and Cy3 
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4. DISCUSSION 
The observation that the emergence of new C. difficile strains is associated with an 
increased incidence and virulence of CDI suggests that strain differences play an important 
role in the onset and subsequent outcome of disease. For this reason, many recent studies 
have focused on the characterisation of the genetic variability found in clinical isolates 
belonging to PCR ribotypes recurrent in outbreaks of CDI (Stabler, Gerding et al. 2006; He, 
Sebaihia et al. 2010; Scaria, Ponnala et al. 2010; Forgetta, Oughton et al. 2011). Among the 
genetic traits considered to be important for pathogenicity, we have chosen to investigate the 
variability of a number of genes coding for a family of surface exposed proteins, the CWPs 
or cell wall proteins.  
Our analysis was carried out on 14 of the 29 known cwp genes in 40 Italian clinical 
isolates that belong to PCR ribotypes 001, 012, 014, 018, 078 and 126. The data have 
provided insight into the extent of sequence variability between strains of different PCR 
ribotypes as well as between different isolates of the same PCR ribotype. On the basis of the 
degree of sequence conservation, these cwp genes could be divided into two groups. One 
comprises 9 highly conserved cwp genes that have identical sequences in all the isolates of 
the same PCR ribotype and only a few polymorphisms between PCR ribotypes, and the other 
group includes 5 variable cwp genes with low sequence conservation between isolates of the 
same PCR ribotype as well as between different PCR ribotypes. Interestingly, the latter group 
comprises cwp27 and cwp29, two genes coding for CWPs that do not contain putative 
domains assigned to a known function (Fagan and Fairweather 2011). A search for sequence 
homology of their unassigned C-terminal regions, however, showed that both have some 
sequence similarity with phage proteins (data not shown); thus implying that these genes 
could have been acquired through horizontal gene transfer events. All the other Cwps contain 
two or three cell wall binding motifs in addition to a unique domain that is proposed to 
specify a function. 
Moreover, the results of our phylogenetic analysis show that certain PCR ribotypes 
always display the same type of variability for most of the cwp genes included in our study. 
This is the case for PCR ribotypes 014 and 018, or 078 and 126. In particular, all ten PCR 
ribotype 078 isolates of our collection have polymorphisms identical to those found in the six 
PCR ribotype 126 strains, while they differ, albeit just for a few nucleotides, from the 078 
reference strains M120 and QCD23M63 (Figure 22).  
This is in agreement with previous studies, where PCR ribotypes 078 and 126 are 
always assigned to the same lineage (Spigaglia, Barbanti et al. 2010; Reil, Erhard et al. 2011), 
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a clade which is frequently associated with livestock as well as with humans (Keel, Brazier et 
al. 2007; Goorhuis, Debast et al. 2008; Hensgens, Keessen et al. 2012). Another interesting 
outcome of our study is the finding that, with regard to cwp gene variability, PCR ribotypes 
078/126 are more closely related to PCR ribotype 027 than to any of the other PCR ribotypes 
analysed (Figure 22). Recently, a number of reports have focused their interest on 
determining which genetic factors PCR ribotypes 027 and 078/126 may have in common that 
would help to explain the similarity in CDI outcome observed for these “hypervirulent” 
strains (Knetsch, Hensgens et al. 2011; Barbut and Rupnik 2012; Walk, Micic et al. 2012). 
Our data clearly suggest that 14 of the 29 predicted CWPs share a high degree of sequence 
similarity in strains that belong to PCR ribotypes 078/126 and 027. As CWPs are surface 
components of C. difficile possibly involved in colonisation and onset of CDI, it is proposed 
that several of the 14 CWPs characterised in this work may represent common traits of these 
PCR ribotypes which contribute to their “hypervirulent” behaviour.  
The genetic diversity found among the six PCR ribotypes is not evenly distributed 
between the 14 cwp genes of interest and can be used to discriminate between highly 
conserved and variable cwp genes. Likewise, expression of conserved CWPs seems to be 
well conserved in all isolates (Figure 23), while variable CWPs are not always expressed at 
comparable levels even in strains containing identical sequences but belonging to different 
PCR ribotypes, as seen for the expression of Cwp27 in PCR ribotype 001 isolates (Figure 25). 
Our results highlight how difficult it is to characterise key components of the C. difficile cell 
surface due to the exceedingly high overall genetic complexity present in different C. difficile 
isolates.  
One approach to identify  the proteins that could be immunogenic is to examine the 
hamster immune response to bacterial infection. This not only provides information about the 
expression of proteins in the host, but also may serve to identify proteins involved in 
pathogenesis. In fact, by the use of protein microarray analysis, some Cwps such as Cwp10, 
CwpV and Cwp21, were shown to be the most immunogenic Cwps under our conditions. The 
majority of the Cwps present on the chip are recombinant proteins, but estimates on their 
expression levels and in vivo exposure are not currently available. 
For these two reasons, the low values obtained for the other Cwps should not be 
interpreted as lack of expression of these proteins in vivo, but they are more easily correlated 
with low immunogenic properties of these Cwps and our experimental approach, which 
involves the use of recombinant proteins. 
The in vitro expression of these proteins was confirmed by our Western blot results. In 
the case of conserved cwp genes, the results obtained are very clear. Indeed, in the case of the 
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extremely variable cwp26 gene, although we were not able to amplify and sequence this 
ortholog in several isolates (Figure 21), expression of a Cwp26-like protein could be detected 
in most of the PCR negative strains. Moreover, in all the PCR ribotype 001, 012, 014 and 018 
strains analysed expression of Cwp26 was observed only in S-layer extracts, indicating that 
Cwp26 is a complex constituent of the S layer in these PCR ribotypes (Figure 24B). The 70 
kDa bands may indicate a propensity of Cwp26 to form stable complexes with other Cwps. 
As it is known that the few Cwps characterized so far are processed (de la Riva, Willing et al. 
2011; Reynolds, Emerson et al. 2011), it cannot be excluded that a similar mechanism also 
applies to the mature form of Cwp26. 
In summary, we propose that the conserved CWPs may correspond to essential 
components of the bacterial surface, while the highly variable CWPs could be more recent 
acquisitions of additional surface elements.  
As the specific function of the majority of the CWPs analysed in our study remains 
unclear, it is not currently possible to elucidate if there is a correlation between the presence 
of a particular Cwp in the S-layer and C. difficile interspecies transmission, or increased 
spread and severity of CDI. All these aspects need to be addressed urgently in order to be 
able to contain the significant increase in disease incidence and mortality reported in recent 
years. Finally, due to the complexity of the genetic variability observed in C. difficile strains, 
a unique method for typing newly emerging strains of C. difficile is still not available. The 
analysis of cwp gene diversity could offer an additional tool for the classification of C. 
difficile clinical isolates. 
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